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Abstract Genetic variants have been associated with the risk
of developing glioma, but functional mechanisms on disease
phenotypic traits remain to be investigated. One phenotypic
trait of glioblastoma is the mutation and amplification of the
epidermal growth factor receptor (EGFR) gene. We investi-
gated associations between pre-diagnostic serum protein con-
centrations of EGFR and ErbB2, both members of the EGFR
family, and future risk of glioma. Further, we studied if EGFR
glioma risk variants were associated with EGFR and ErbB2
serum levels. We assessed the associations between genetic
glioma risk variants and serum concentrations of EGFR and
ErbB2, asmeasured in pre-diagnostic cohort serum samples of
593 glioma patients and 590 matched cancer-free controls.
High serum EGFR and ErbB2 levels were associated with risk
of developing glioblastoma (P = 0.008; OR= 1.58, 95 %
CI = 1.13–2.22 and P=0.017, OR=1.63, 95 % CI= 1.09–
2.44, respectively). High serum ErbB2 concentration was also
associated with glioma risk overall (P=0.049; OR=1.39,
95 % CI=1.00–1.93). Glioma risk variants were not associat-
ed with high serum protein abundance. In contrast, the EGFR
risk variant rs4947986 (T) was correlated with decreased
EGFR serum levels (study cohort P= 0.024 and controls
P=0.009). To our knowledge, this is the first study showing
an association of EGFR and ErbB2 serum levels with glioma
more than a decade before diagnosis, indicating that EGFR
and ErbB2 serum proteins are important in early
gliomagenesis. However, we did not find evidence that glioma
risk variants were associated with high pre-diagnostic serum
concentrations of EGFR and ErbB2.
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Introduction
The incidence of gliomas is approximately six new diagnosed
cases per 100,000 inhabitants per year [1]. The 5-year survival
rate for patients with glioblastomas has improved with com-
bined chemoradiotherapy, but still most patients are not long-
term survivors [2]. Curative treatment is rare due to the infil-
trative growth of the tumor [3]. General cancer risk factors,
such as alcohol and smoking, have not been associated with
brain tumors [4] and currently there is no sufficient knowledge
of the etiology of gliomas. Established glioma risk factors are
ionizing radiation, hereditary syndromes, and increasing age,
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whereas asthma and allergy are inversely associated with the
risk of developing gliomas [5, 6]. Increasing evidence sup-
ports a genetic component in glioma etiology, including both
observations of familiar aggregation of gliomas [7–9] and ob-
servations of nine single nucleotide polymorphisms (SNPs)
being associated with risk of developing gliomas, identified
through large scale genome-wide association studies (GWAS)
[10–14] (Table 1). Additional polymorphisms suggested to be
associated with glioma risk include rs4947979 and rs4947986
at 7p11.2 (EGFR), identified by our group through a candidate
gene approach [15] (Table 1). In another study, rs4947986 was
associated with poor survival, although failing replication in a
validation dataset [16].
EGFR is mutated and amplified in up to 70 % of primary
glioblastomas [17, 18]. The EGFR family consists of four
receptor tyrosine kinases: EGFR (ErbB1), Her2 (ErbB2),
Her3 (ErbB3), and Her4 (ErbB4) [19]. EGFR familymembers
are involved in many cellular processes, for example, cell
proliferation and apoptosis, and are known to play a central
role in development and progression in different types of can-
cer [20]. Deregulated EGFR signaling has been identified as a
critical driver in glioblastoma tumor initiation and progression
[21, 22]. Structural studies revealed that the extracellular re-
gion of EGFR is induced to homo- or heterodimerize after
growth factor binding resulting in an allosteric activation of
the intracellular tyrosine kinase domain [23]. However, there
are multiple mechanisms causing deregulated epidermal
growth factor (EGF) receptor signaling in glioblastomas, such
as (i) increased EGFR abundance through gene amplification
and/or increased gene translation, (ii) increased abundance of
EGFR through autocrine loops, and (iii) mutations rendering
the receptor constitutively active [22].
EGFR gene mutations are in the majority of glioblastomas
accompanied by regional DNA amplification, leading to a
higher number of copies of the mutated allele. The Cancer
Genome Atlas (TCGA) consortium identified six somatic mu-
tations in glioblastomas that affect EGFR protein structure,
ranging from extracellular domain point mutations and dele-
tions to deletions in the cytoplasmic tail of the receptor [24].
The aberrant exon 1–8 junction characteristic of EGFRvIII
(Δe 2–7 vIII deletion) was highly expressed in some of the
tumors investigated by TCGA. Although the biological or
clinical relevance of EGFRvIII expression remains to be dem-
onstrated, EGFRvIII expression in glioblastoma cells confers
a more aggressive tumor phenotype [24, 25]. Three different
C-terminal rearrangements, targeting the cytoplasmic domain
of EGFR, were also detected [24]. C-terminal deletion vari-
ants have been associated with gliomagenesis in experimental
rodent systems in vivo [26]. Furthermore, two relatively
uncharacterized recurrent EGFR variants, deletions of exons
12–13 (Δe12–13) and exons 14–15 (Δe14–15) were identi-
fied by TCGA. Both Δe12–13 and Δe14–15 appear to be
expressed in minor allelic fractions (<10 %), raising the ques-
tion of whether they result from splicing aberration or geno-
mic deletion [24]. This shows that somatic events inEGFR are
common and complex and that studies of tumor heterogeneity
assumes that it also is an early event as it was evident in all
parts of the tumor [27].
The identified genetic risk variants for glioma are mostly
mapping to intronic or intergenic parts of the genome, with no
known function. To gain a better understanding of glioma
etiology, the potential function of these variants requires fur-
ther investigation. In this study, we investigated if there is a
correlation between genetic glioma risk variants and levels of
EGFR and ErbB2 in pre-diagnostic sera from glioma patients
and matched controls. In particular, our investigation focused
on four polymorphisms located in or close to the EGFR gene.
The SNPs rs11979158 and rs4947979 are both located in in-
tron 1, while rs4947986 maps to the intron-exon boundary in
exon 6 or 7 of the EGFR gene, depending on the transcript.
The fourth SNP in focus was rs2252586, which is located
107 kb downstream of EGFR.
Materials and methods
Biological samples
The study was designed as a nested case‐control study within
the Janus Serum Bank of Norway [28]. Detailed descriptions
of the Janus repository and the present study population have
been published recently [29]. In brief, we identified 593 glio-
ma cases by linking the Janus cohort to the Cancer Registry of
Norway. Cases were diagnosed on average 15 years after
blood sample collection. A total of 590 cancer-free controls
were individually matched on the basis of sex, year of birth
(within 15 months), county, and date of sample collection
(within 4 months). All pre-diagnostic serum samples were
donated between 1972 and 2004 and stored at −25 °C at the
Janus repository. Most of the samples came from people in
Table 1 Genetic variants associated with glioma
SNPa Locus Gene Reference
rs4295627 8q24.21 CCDC26 [10]
rs498872 11q23.3 PHLDB1 [10]
rs6010620 20q13.33 RTEL1 [10]
rs4977756 9p21.3 CDKN2B-AS1 [10]
rs1412829 9p21.3 CDKN2B-AS1 [11]
rs2252586 7p11.2 EGFR [12]
rs11979158 7p11.2 EGFR [12]
rs78378222 17p13.1 TP53 [13, 14]
rs4947979 7p11.2 EGFR [15]
rs4947986 7p11.2 EGFR [15]
a Variants detected by means of GWAS in bold
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their forties undergoing health surveys of cardiovascular dis-
ease risk. Health examination samples collected between 1974
and 1978 were collected in vacutainer tubes containing 5 mg
iodoacetate (n=388). Around 10 % of the samples of the
Janus cohort were collected from Red Cross Blood Bank do-
nors. Red Cross blood donor samples collected between 1973
and 1975 were lyophilized (n = 75). All other samples
underwent no special procedures after collection. The study
was approved by the ethical review board at the University of
Oslo, Norway.
DNA amplification
Five-microliter aliquots of serumwere transferred into 96-well
microplates (Axygen, VWR, Oslo, Norway) and subjected to
enzymatic amplification, as described by Ekstrøm et al. [30].
Serum aliquots were denatured and PCR master mix was
added to each well, and plates were subjected to temperature
cycling as described [29].
Variant detection
Amplified 6-FAM (6-carboxyfluorescein, single isomer) la-
beled PCR products were analyzed by denaturant capillary
electrophoresis on a MegaBACE 1000 DNA Analysis
System (GE Healthcare Bio-Sciences AB, Uppsala,
Sweden). The base variants were separated by cycling tem-
perature capillary electrophoresis (CTCE), with separating
temperatures. The variants were identified by co-analysis with
a mutated internal standard, essentially as described by
Bjørheim et al. [31]. The assay was run in a 96-well format,
where a minimum of two wells per microplate were used for
controls, i.e. one serum control (pool of sera from five healthy
individuals) and at least one negative control without serum
template. The genetic variants analyzed were selected from
previous GWAS and candidate genes including rs11979158,
rs2252586, rs4947979, rs4947986 (all EGFR), rs1412829,
rs4977756 (both CDKN2B-AS1), rs2736100 (TERT),
rs4295627 (CCDC26), rs498872 (PHLDB1), rs6010620
(RTEL1), rs78378222 (TP53), and rs1476278 (PGAP3)
(Tables 3 and 4), as described by Wibom et al. [29].
EGFR and ErbB2 serum detection
EGFR and ErbB2 serum levels were measured by a multiplex
immunoassay (Meso Scale Discovery (MSD), Gaithersburg,
MD, USA) according to the manufacturer’s protocol. Multi-
Spot® 96-well plates fromMSD were coated by the manufac-
turer with two different antigens to capture antibodies against
EGFR and ErbB2 in human serum samples. All Multi-Spot®
96-well plates were ordered in a single lot to reduce inter-
assay variation. Reagents used for the multiplex immunoassay
were fromMSD, if not stated separately. Recombinant human
EGFR (R&D Systems Europe Ltd, Oxon, UK) and ErbB2
(eBioscience, Inc. CA, USA) were diluted in diluent 9 to pre-
pare a calibration mix for the standard curves. Each well in the
antigen-coated plates were incubated with 150 μl blocking
solution C at room temperature for 1 h with shaking and
washed three times with phosphate-buffered saline containing
0.05 % Tween 20 (PBS-T). Diluent 7 were added to each well
and thereafter 25 μl of calibrator mix, internal controls, or
samples were added to each well. The plates were sealed
and incubated at room temperature for 2 h on a shaker and
then washed three times with PBS-T. After that 25 μl multi-
plex detection antibody mix (containing Sulfo-Tag-labeled
secondary antibodies against EGFR and ErbB2, Sulfo-Tag-
labeled streptavidin, D-R blocker, D-M blocker, and diluent
8) was added. The plates were sealed and incubated at room
temperature for 2 h on a shaker and then washed three times in
PBS-T. Finally, 150 μl of MSD Read Buffer-T was added to
each well. Quantification of protein concentrations was per-
formed with MSD sector imager model no. 2400. Each ana-
lyzed assay plate included, a standard curve, case-control sam-
ples (blinded and placed in random order), and two laboratory
control samples allowing to monitor inter-assay variation.
Quality control
The quality of the genotype data was assessed by calculating
call rates for both samples and genotypes. Samples that
displayed a genotyping call rate of <80 % (i.e., where the
genotyping had failed at >2 variants) were removed from fur-
ther analyses involving genotype data. We also tested the ge-
notype frequency distribution among controls for each SNP
against the Hardy-Weinberg equilibrium (HWE) to identify
potential genotyping errors. Among the serum protein abun-
dance data, values outside mean±5 standard deviations were
removed as outliers.
Statistical analysis
To investigate associations between protein abundance in se-
rum and risk of disease, we applied conditional logistic regres-
sion both to untransformed continuous abundance data and to
dichotomized abundance data, where the median of the con-
trol population (EGFR 57.517 ng/ml; ErbB2 1.857 ng/ml)
was used as cutoff for categorization. To investigate correla-
tions between protein abundance in serum and a given geno-
type, we applied an additive linear regression model (as the
samples were not matched for these analyses) and included the
following covariates: sex, storage time, sample lyophilization,
addition of iodoacetate, and analysis batch. We performed
separate analyses for the following groups: all cases, cases
with blood sample donation within 5 years to diagnosis, glio-
blastomas, oligodendrogliomas, astrocytomas, controls, and
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the entire study cohort. All analyses were performed using the
R software for statistical computing (www.R-project.org).
Results
Genotyping was successful for 1178 of 1183 samples. All
included variants displayed a call rate of >90 % and a HWE
P value >0.005, i.e., there was no indication of genotyping
errors. The quantification of serum levels of EGFR and ErbB2
was successful in all but five instances. One sample failed for
both EGFR and ErbB2, and the ErbB2 values from three
additional samples were removed as outliers.
The characteristics of the study population are represented
in Table 2. Time from blood sample collection to case diag-
nosis was 14.7 years (median) and ranged from 2 months to
35 years. We found no evidence for a correlation between
serum levels of neither EGFR nor ErbB2 and time between
sampling and diagnosis, P=0.499 and P=0.221 respectively.
EGFR levels appeared to increase in correlation with storage
time (P=0.014), as assessed by linear regression adjusted for
sex, analysis batch variation, addition of iodoacetate, and sam-
ple lyophilization.We noticed a similar trend for ErbB2 levels,
although not significant (P=0.279). By the same analysis ap-
proach, both EGFR and ErbB2 were found having higher
levels in males than in females (P = 4.625 × 10−6 and
P=1.960×10−6 respectively).
We assessed the associations between serum protein con-
centrations and disease risk (overall and by histological sub-
type) using both untransformed continuous abundance data
and dichotomized abundance data. By dichotomizing the
abundance variables, we found an association between high
pre-diagnostic EGFR concentration and risk of glioblastoma
(P=0.008; OR=1.58, 95 % CI=1.13–2.22), as well as asso-
ciations between high pre-diagnostic ErbB2 concentration and
overall risk for glioma (P=0.049; OR=1.39, 95 % CI=1.00–
1.93) and glioblastoma (P = 0.017, OR = 1.63, 95 %
CI = 1.09–2.44). We could not confirm these observations
when investigating continuous abundance data and glioma
risk (all P>0.05). Median serum protein concentrations are
shown for cases and controls in Table 2. Density plots were
applied to visualize continuous distributions of serum protein
levels for cases and controls (Supplementary figure 1).
Possible correlations between risk SNPs and serum levels
of EGFR and ErbB2 were analyzed. The analyses were per-
formed separately for overall glioma cases, glioma subtypes,
control individuals, and the entire study cohort, including both
cases and controls. All results are listed in Tables 3 and 4.
Among the EGFR gene variants included in the study, we
found a correlation between rs4947986 and decreased EGFR
serum levels (P=0.024), as observed in the entire study co-
hort. The association seemed accentuated among controls
(P=0.009). Similar trends were observed in major histologic
subtypes investigated, albeit not statistically significant
(P>0.05). Another EGFR gene variant, rs4947979, correlated
with lower EGFR concentration in oligodendroglioma cases
(P=0.050).
The weak correlations between risk variants of CCDC26,
PGAP3, and PHLDB1 and serum protein concentration,
which were not corresponding to our predefined hypothesis,
are even presented in Tables 3 and 4.
None of the described correlations of genotypes with serum
protein levels were significant after adjusting for multiple
testing.
Discussion
Numerous studies have found an association between the ex-
pression of EGFR and its heterodimerization partner ErbB2
Table 2 Characteristics of the study population
Cases Controlsa
N % N %
593 100 590 100
Sex
Female 199 33.6 198 33.6
Male 394 66.4 392 66.4
Age at sampling (years)
18–30 53 8.9 55 9.3
31–40 220 37.1 213 36.1
41–50 295 49.8 296 50.2
51–60 8 1.3 9 1.5
61–70 16 2.7 15 2.6
71–75 1 0.2 2 0.3
Year of sampling
1972–1985 283 47.7 280 47.5
1986–1991 246 41.5 248 42.0
1992–1997 60 10.1 58 9.8






Other subtypes 43 7.2
Time from sampling to diagnosis
Mean ± SD (years) 15.2 ± 8.6
Median serum protein level
EGFR (ng/ml) 58.35 57.52
ErbB2 (ng/ml) 1.95 1.86
a Controls were matched to cases on sex, age (± 15 months), and date of
sample collection (± 4 months)
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within different tumors [32–34], including gliomas [35–37].
Identifying nine glioma susceptibility loci, GWA studies have
provided further information about glioma etiology, although
it is unclear how these risk variants initiate pathogenic effects.
This missing information offered a compelling rationale for
our study: we investigated potential associations between
known glioma risk variants and pre-diagnostic serum levels
of EGFR and ErbB2. In addition, we evaluated the association
between the risk for glioma and pre-diagnostic serum levels of
EGFR and ErbB2 using both dichotomized and continuous
protein abundance data to understand if chronic activation
and high levels of the receptors could be a mechanism in
gliomagenesis. By dichotomizing pre-diagnostic serum pro-
tein concentration according to the median of the control pop-
ulation, we found that both high levels of EGFR and ErbB2
were associated with glioblastoma risk. High serum concen-
tration of ErbB2 was also associated with glioma risk overall.
A chance finding cannot be ruled out, as the correlations were
not evident when analyzing continuous data. It is possible,
however, that specific cutoff values need to be exceeded to
initiate gliomagenesis, a phenomena that has been observed
for high levels of pre-diagnostic C-reactive protein and the
genesis of ovarian cancer [38].
To our knowledge, pre-diagnostic serum EGFR and ErbB2
concentrations have not been studied in glioma, although it is
known that elevated serum EGFR in samples taken at glioma
diagnosis is associated with worse prognosis [39]. In our
study, the long lag time (almost 15 years) between sample
donation and glioblastoma diagnosis indicates that increased
serum EGFR and ErbB2 are likely to be associated with an
etiological factor more than with the effects of undiagnosed
disease (i.e., reverse causation). Given that the blood-brain
barrier is expected to be intact such a long time before diag-
nosis, it might be speculated that the observed serum protein
perturbations may take their origin outside of the central ner-
vous system (e.g., due to environmental factors). Elevated
serum protein abundance could be a tumor-initiating factor
as, for example, is the case for chronic inflammation due
to hepatitis C which can precede liver cancer and lympho-
ma [40].
Table 3 Trends for EGFR serum levels for glioma subtypes and controls depending on genotype
SNP Gene Alleles Cases Glioma GBM Oligo Astro Casesa Controls Study-cohort
Major│Minor <5 years
rs11979158 EGFR T│C ns ns ns ns ns ns ns ns
↑ ↑ ↑ ↓ ↓ ↑ ↓ ↑
rs1412829 CDKN2B T│C ns ns ns ns ns ns ns ns
↑ ↑ ↑ ↓ ↓ ↑ ↓ ↑
rs1476278 PGAP3 C│T ns ns ns ns ns ns ns ns
↓ ↓ ↑ ↓ ↓ ↑ ↓ ↓
rs2252586 EGFR C|T ns ns ns ns ns ns ns ns
↓ ↓ ↓ ↑ ↑ ↑ ↓ ↓
rs2736100 TERT G|T ns ns ns ns ns ns ns ns
↑ ↑ ↑ ↑ ↓ ↑ ↑ ↑
rs4295627 CCDC26 T|G ns ns ns ns ns 0.03 ns ns
↑ ↑ ↑ ↓ ↑ ↑ ↑ ↑
rs4947979 EGFR A|G ns ns ns 0.05 ns ns ns ns
↓ ↓ ↓ ↓ ↑ ↑ ↓ ↓
rs4947986 EGFR C|T ns ns ns ns ns ns 0.009 0.02
↓ ↓ ↓ ↓ ↓ ↑ ↓ ↓
rs4977756 CDKN2A/2B A|G ns ns ns ns ns ns ns ns
↑ ↑ ↑ ↑ ↓ ↑ ↓ ↓
rs498872 PHLDB1 G|A ns ns ns ns ns ns ns ns
↓ ↑ ↑ ↑ ↓ ↓ ↓ ↓
rs6010620 RTEL1 G|A ns ns ns ns ns ns ns ns
↓ ↓ ↓ ↑ ↑ ↑ ↓ ↓
rs78378222 TP53 A|C ns ns ns nd ns nd ns ns
↓ ↓ ↓ ↓ ↑ ↓
Arrows indicate higher (↑) or lower (↓) serum EGFR for the risk allele (significant trends and risk allele in bold)
ns not significant, nd not determined, GBM glioblastoma, Oligo oligodendroglioma, Astro astrocytoma
a Cases with sample donation 0–5 years before diagnosis
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Both EGFR and ErbB2 serum levels displayed no detectable
correlation with time between sampling and diagnosis. Because
we did not have access to repeated pre-diagnostic samples, we
could not dismiss concentration changes over time on the indi-
vidual level. Ligand-mediated chronic activation of EGFR is
necessary for gliomagenesis in mice [41], and this association
might be consistent with our finding of time-stable, elevated
serum EGFR and ErbB2 levels in glioblastomas. The mecha-
nisms behind enhanced oncogenic signaling due to EGFR are
extremely complex. For example, the activation of autocrine
loops due to EGF ligands causes constitutive receptor activa-
tion [22]. Taking this process into account would have im-
proved our study, but a broader screening of serum protein
levels was not possible due to the limited volume of sera.
However, EGFR activation and EGFR serum levels differ bio-
logically: EGFR activation is an intracellular process, and se-
rum levels of EGFR reflect extracellular protein concentrations.
There is high haplotype variability in the EGFR gene, and
we analyzed a limited set of four polymorphisms, where one
of them showed an association with lower serum EGFR. All
four investigated genetic variants are independent of each oth-
er in terms of linkage disequilibrium. The underlying mecha-
nisms connecting the observed association between genotype
and serum levels are not clear. The polymorphism rs4947986
is located 47 bases from the boundary of exon 7 that is part of
the extracellular domain II which is critical to EGFR dimer-
ization [23, 42]. It is plausible that it is linked with a, hitherto
unidentified, variant that in turn affects the protein sequence.
Considering the genomic location, changes to the protein se-
quence or structure may have large effects on the protein’s
physical properties, potentially affecting dimerization.
Further understanding of the interactions between genetic var-
iants and associations with haplotypes would require a fine
mapping of the EGFR region in pre-diagnostic samples from
other cohorts. In addition, matched blood and tumor samples
with information regarding the exact type of somatic EGFR
mutations would help classify more specific subgroups and
enable identification of stronger associations.
Our study had some limitations. All genotype-phenotype
associations we present here were not significant following
Table 4 Trends for ErbB2 serum levels for glioma subtypes and controls depending on genotype
SNP Gene Alleles Cases Glioma GBM Oligo Astro Casesa Controls Study-cohort
Major│Minor <5 years
rs11979158 EGFR T│C ns ns ns ns ns ns ns ns
↑ ↑ ↑ ↑ ↑ ↓ ↓ ↑
rs1412829 CDKN2B T│C ns ns ns ns ns ns ns
↑ ↑ ↑ ↓ ↑ ↑ ↑ ↑
rs1476278 PGAP3 C|T ns ns ns 0.05 0.05 ns ns ns
↓ ↓ ↓ ↓ ↓ ↑ ↓ ↓
rs2252586 EGFR C|T ns ns ns ns ns ns ns ns
↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
rs2736100 TERT G|T ns ns ns ns ns ns ns ns
↑ ↓ ↓ ↓ ↑ ↑ ↑ ↑
rs4295627 CCDC26 T|G ns ns ns ns ns ns ns ns
↑ ↑ ↑ ↓ ↓ ↑ ↓ ↓
rs4947979 EGFR A|G ns ns ns ns ns ns ns ns
↑ ↑ ↑ ↓ ↓ ↑ ↑ ↑
rs4947986 EGFR C|T ns ns ns ns ns ns ns ns
↑ ↑ ↑ ↑ ↓ ↑ ↓ ↓
rs4977756 CDKN2A/2B A|G ns ns ns ns ns ns ns ns
↑ ↑ ↑ ↓ ↑ ↑ ↑ ↑
rs498872 PHLDB1 G|A ns ns ns ns ns 0.005 ns ns
↓ ↓ ↓ ↓ ↓ ↓ ↑ ↓
rs6010620 RTEL1 G|A ns ns ns ns ns ns ns ns
↑ ↑ ↑ ↑ ↓ ↑ ↓ ↓
rs78378222 TP53 A|C ns ns ns nd ns nd ns ns
↓ ↓ ↓ ↑ ↓ ↓
Arrows indicate higher (↑) or lower (↓) serum ErbB2 concentration for the risk allele (significant trends and risk allele in bold)
ns not significant, nd not determined, GBM glioblastoma, Oligo oligodendroglioma, Astro astrocytoma
a Cases with sample donation 0–5 years before diagnosis
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adjustment to both the family-wise error rate (Bonferroni cor-
rection) and the false discovery rate (Benjamini-Hochberg pro-
cedure). Both procedures to adjust for multiple testing might be
too stringent and imply the risk of false-negative findings be-
cause some investigated variables are not independent and due
to the experimental design and the hypothesis-driven character
of our study. Another limitation concerns EGFR variants
rs4947979 and rs4947986. These variants were suggested to
be associated with gliomas by a candidate gene approach that
included 728 glioma individuals [15]. Recently, our group
found that both SNPs may primarily be associated with
prolonged survival rather than with risk in 598 glioma cases
[29]. However, the two variants might be important to the mu-
tation cascade occurring in EGFR during glioma tumorigenesis.
Our data provide first evidence that increased serum EGFR
and ErbB2 levels can be detected in glioblastoma patients
more than a decade before diagnosis, indicating that both pro-
teins are important early in gliomagenesis. To confirm these
results, we will need broader collaborations with other centers
that collect longitudinal data using similar approaches. Further
studies of EGFR and gene-environment interaction will be
performed in existing and recently collected case-control stud-
ies (Amirian et al., unpublished manuscript) to understand the
interaction between genetic variants and environmental fac-
tors such as asthma, allergy, and smoking.
Compliance with ethical standards
Funding This study was supported by Acta Oncologica foundation
through the Royal Swedish Academy of Science (BM salary), The
Swedish Research Council, Swedish Cancer foundation, Northern
Sweden Cancer foundation, Umeå University Young investigator reward,
and Umeå Hospital cutting edge grant.
Conflicts of interest None
Ethical approval All procedures involving human participants were in
accordance with the ethical standards of the institutional and national
research committee and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statisti-
cal report: primary brain and central nervous system tumors diag-
nosed in the United States in 2005–2009. Neuro Oncol. 2012;14
suppl 5:v1–v49. doi:10.1093/neuonc/nos218.
2. Asklund T, Malmström A, Bergqvist M, Björ O, Henriksson R.
Brain tumors in Sweden: data from a population-based registry
1999–2012. Acta Oncol. 2015;54(3):377–84. doi:10.3109/
0284186X.2014.975369.
3. Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of
recurrent high-grade astrocytoma. J Clin Oncol. 2006;24(8):1273–
80. doi:10.1200/jco.2005.04.7522.
4. Braganza MZ, Rajaraman P, Park Y, Inskip PD, Freedman ND,
Hollenbeck AR, et al. Cigarette smoking, alcohol intake, and risk
of glioma in the NIH-AARP Diet and Health Study. Br J Cancer.
2014;110(1):242–8. doi:10.1038/bjc.2013.611.
5. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis
FG, Il’yasova D, et al. Brain tumor epidemiology: consensus from
the Brain Tumor Epidemiology Consortium. Cancer. 2008;113(S7):
1953–68. doi:10.1002/cncr.23741.
6. Schwartzbaum J, Ding B, Johannesen TB, Osnes LTN, Karavodin
L, Ahlbom A, et al. Association between prediagnostic IgE levels
and risk of glioma. J Natl Cancer Inst. 2012;104(16):1251–9. doi:
10.1093/jnci/djs315.
7. Malmer B, Henriksson R, Grönberg H. Familial brain tumours—
genetics or environment? A nationwide cohort study of cancer risk
in spouses and first-degree relatives of brain tumour patients. Int J
Cancer. 2003;106(2):260–3. doi:10.1002/ijc.11213.
8. ScheurerME, Etzel CJ, LiuM, El-Zein R, Airewele GE,Malmer B,
et al. Aggregation of cancer in first-degree relatives of patients with
glioma. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2491–5.
doi:10.1158/1055-9965.epi-07-0576.
9. WrenschM, Lee M, Miike R, Newman B, Bargar G, Davis R, et al.
Familial and personal medical history of cancer and nervous system
conditions among adults with glioma and controls. Am J
Epidemiol. 1997;145(7):581–93.
10. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M,
Malmer B, et al. Genome-wide association study identifies five
susceptibility loci for glioma. Nat Genet. 2009;41(8):899–904.
http://www.nature.com/ng/journal/v41/n8/suppinfo/ng.407_S1.
html.
11. Wrensch M, Jenkins RB, Chang JS, Yeh R-F, Xiao Y, Decker PA,
et al. Variants in the CDKN2B and RTEL1 regions are associated
with high-grade glioma susceptibility. Nat Genet. 2009;41(8):905–
8. http://www.nature.com/ng/journal/v41/n8/suppinfo/ng.408_S1.
html.
12. Sanson M, Hosking FJ, Shete S, Zelenika D, Dobbins SE, Ma Y,
et al. Chromosome 7p11.2 (EGFR) variation influences glioma risk.
Hum Mol Genet. 2011;20(14):2897–904. doi:10.1093/hmg/
ddr192.
13. Enciso-Mora V, Hosking FJ, Di Stefano AL, Zelenika D, Shete S,
Broderick P, et al. Low penetrance susceptibility to glioma is caused
by the TP53 variant rs78378222. Br J Cancer. 2013;108(10):2178–
85. doi:10.1038/bjc.2013.155.
14. Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J,
Gudbjartsson DF, et al. A germline variant in the TP53
polyadenylation signal confers cancer susceptibility. Nat Genet.
2011;43(11):1098–103. http://www.nature.com/ng/journal/v43/
n11/abs/ng.926.html#supplementary-information.
15. Andersson U, Schwartzbaum J, Wiklund F, Sjöström S, Liu Y,
Tsavachidis S, et al. A comprehensive study of the association
between the EGFR and ERBB2 genes and glioma risk. Acta
Oncol. 2010;49(6):767–75. doi:10.3109/0284186X.2010.480980.
16. Sjöström S, Andersson U, Liu Y, Brännström T, Broholm H,
Johansen C, et al. Genetic variations in EGF and EGFR and glio-
blastoma outcome. Neuro Oncol. 2010;12(8):815–21. doi:10.1093/
neuonc/noq018.
17. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and
rearranged epidermal growth factor receptor genes in human glio-
blastomas reveal deletions of sequences encoding portions of the N-
Tumor Biol. (2016) 37:11065–11072 11071
and/or C-terminal tails. Proc Natl Acad Sci. 1992;89(10):4309–13.
doi:10.1073/pnas.89.10.4309.
18. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre
P-L, et al. Genetic pathways to glioblastoma: a population-based
study. Cancer Res. 2004;64(19):6892–9. doi:10.1158/0008-5472.
can-04-1337.
19. Pan D, Lin X. Epithelial growth factor receptor-activated nuclear
factor [kappa]B signaling and its role in epithelial growth factor
receptor-associated tumors. Cancer J. 2013;19(6):461–7. doi:10.
1097/PPO.0000000000000001.
20. Roskoski Jr R. The ErbB/HER family of protein-tyrosine kinases
and cancer. Pharmacol Res. 2014;79(0):34–74. doi:10.1016/j.phrs.
2013.11.002.
21. Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden
S, Pfannl R, et al. Oncogenic EGFR signaling cooperates with loss
of tumor suppressor gene functions in gliomagenesis. Proc Natl
Acad Sci. 2009;106(8):2712–6. doi:10.1073/pnas.0813314106.
22. Huang PH, Xu AM, White FM. Oncogenic EGFR signaling net-
works in glioma. vol 87. 2009.
23. Lemmon MA, Schlessinger J, Ferguson KM. The EGFR family:
not so prototypical receptor tyrosine kinases. Cold Spring Harb
Perspect Biol. 2014;6(4). doi:10.1101/cshperspect.a020768.
24. Brennan Cameron W, Verhaak Roel GW, McKenna A, Campos B,
Noushmehr H, Salama Sofie R, et al. The somatic genomic land-
scape of glioblastoma. Cell. 2013;155(2):462–77. doi:10.1016/j.
cell.2013.09.034.
25. Inda M-d-M, Bonavia R, Mukasa A, Narita Y, Sah DWY,
Vandenberg S, et al. Tumor heterogeneity is an active process main-
tained by a mutant EGFR-induced cytokine circuit in glioblastoma.
Genes Dev. 2010;24(16):1731–45. doi:10.1101/gad.1890510.
26. Cho J, Pastorino S, Zeng Q, Xu X, JohnsonW, Vandenberg S, et al.
Glioblastoma-derived epidermal growth factor receptor carboxyl-
terminal deletion mutants are transforming and are sensitive to
EGFR-directed therapies. Cancer Res. 2011;71(24):7587–96. doi:
10.1158/0008-5472.can-11-0821.
27. Sottoriva A, Spiteri I, Piccirillo SGM, Touloumis A, Collins VP,
Marioni JC, et al. Intratumor heterogeneity in human glioblastoma
reflects cancer evolutionary dynamics. Proc Natl Acad Sci.
2013;110(10):4009–14. doi:10.1073/pnas.1219747110.
28. Jellum E, Andersen A, Lund-Larsen P, Theodorsen L, Orjasaeter H.
Experiences of the Janus Serum Bank in Norway. Environ Health
Perspect. 1995;103 Suppl 3:85–8.
29. WibomC, Späth F, Dahlin AM, Langseth H, Hovig E, Rajaraman P
et al. Investigation of established genetic risk variants for glioma in
pre-diagnostic samples from a population based nested case control
study. Cancer Epidemiol Biomarkers Prev. 2015. doi:10.1158/
1055-9965.epi-14-1106.
30. Ekstrøm PO, Bjørge T, DørumA, Longva AS, Heintz K-M,Warren
DJ, et al. Determination of hereditarymutations in the BRCA1 gene
using archived serum samples and capillary electrophoresis. Anal
Chem. 2004;76(15):4406–9. doi:10.1021/ac049788k.
31. Bjørheim J, Gaudernack G, Giercksky K-E, Ekstrøm PO. Direct
identification of all oncogenic mutants in KRAS exon 1 by cycling
temperature capillary electrophoresis. ELECTROPHORESIS.
2003;24(1–2):63–9. doi:10.1002/elps.200390032.
32. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al.
EGFR mutations in lung cancer: correlation with clinical response
to gefitinib therapy. Science. 2004;304(5676):1497–500. doi:10.
1126/science.1099314.
33. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications
of the ErbB/epidermal growth factor (EGF) receptor family and its
ligands in ovarian cancer. Biochimica et Biophysica Acta (BBA) -
Reviews on Cancer. 2008;1785(2):232–65. doi:10.1016/j.bbcan.
2008.01.001.
34. Tomas A, Futter CE, Eden ER. EGF receptor trafficking: conse-
quences for signaling and cancer. Trends Cell Biol. 2014;24(1):26–
34. doi:10.1016/j.tcb.2013.11.002.
35. The Cancer Genome Atlas Research N. Comprehensive genomic
characterization defines human glioblastoma genes and core path-
ways. Nature. 2008;455(7216):1061–8. doi:10.1038/nature07385.
36. Yan M, Parker BA, Schwab R, Kurzrock R. HER2 aberrations in
cancer: implications for therapy. Cancer Treat Rev. 2014;40(6):
770–80. doi:10.1016/j.ctrv.2014.02.008.
37. Andersson U, Guo D, Malmer B, Bergenheim AT, Brännström T,
Hedman H, et al. Epidermal growth factor receptor family (EGFR,
ErbB2–4) in gliomas and meningiomas. Acta Neuropathol.
2004;108(2):135–42. doi:10.1007/s00401-004-0875-6.
38. Ose J, Schock H, Tjønneland A, Hansen L, Overvad K, Dossus L
et al. Inflammatory markers and risk of epithelial ovarian cancer by
tumor subtypes: the EPIC cohort. Cancer Epidemiol Biomarkers
Prev. 2015. doi:10.1158/1055-9965.epi-14-1279-t.
39. MQ. Epidermal growth factor receptor serum levels and prognostic
value in malignant gliomas. Tumori. 2007;93(3):275–80.
40. Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A,
et al. Hepatitis C virus syndrome: a constellation of organ- and non-
organ specific autoimmune disorders, B-cell non-Hodgkin’s lym-
phoma, and cancer. World J Hepatol. 2015;7(3):327–43. doi:10.
4254/wjh.v7.i3.327.
41. Acquaviva J, Jun HJ, Lessard J, Ruiz R, Zhu H, Donovan M, et al.
Chronic activation of wild-type epidermal growth factor receptor
and loss of Cdkn2a cause mouse glioblastoma formation. Cancer
Res. 2011;71(23):7198–206. doi:10.1158/0008-5472.can-11-1514.
42. Dawson JP, Berger MB, Lin C-C, Schlessinger J, Lemmon MA,
Ferguson KM. Epidermal growth factor receptor dimerization and
activation require ligand-induced conformational changes in the
dimer interface. Mol Cell Biol. 2005;25(17):7734–42. doi:10.
1128/mcb.25.17.7734-7742.2005.
11072 Tumor Biol. (2016) 37:11065–11072
